Emerge Law Group

On Friday, 8/9, the FDA released its decision to not approve M**A-assisted therapy for PTSD, stirring ongoing debate in the psychedelic research community. Many in the field were optimistic when Lykos Therapeutics initially submitted their New Drug Application in Dec. 2023, pointing to promising Phase 3 trials showing that over 70% of participants no longer met PTSD criteria after M**A treatment. Anticipation of approval lessened significantly in June, however, when the FDA’s advisory committee recommended against approval of M**A-assisted therapy. Despite support from veterans, mental health professionals, and politicians, the FDA cited concerns about the quality of the research and overall safety and efficacy of the drug. Lykos says it plans to seek reconsideration of the decision. But this process will delay the therapy's availability for years, at least.

While some experts view the FDA’s decision as overly cautious, fearing it could stifle innovation in psychedelic therapies, others believe that the rejection might prompt stronger competition and better research quality in the future. The ruling also highlights the broader policy and regulatory challenges facing the psychedelic industry, bringing to light concerns about data quality, clinical trial designs, and the influence of public pressure on regulatory decisions. Despite this setback, Lykos says it remains committed to pushing forward with further research and regulatory efforts. Meanwhile others have been suggesting that psilocybin may now be on track to gain approval ahead of M**A.

Emerge Law Group shareholder Sean Clancy had this to say: “FDA’s decision is not a surprise, given the advisory committee’s prior recommendation against approval. But it certainly is a disappointment for Lykos and others wishing for M**A to be legalized as mental health medicine. Many are speculating about FDA’s exact rationale. And although Lykos will ask FDA to reconsider, it’s safe to assume that Lykos probably needs to revisit its methods and protocols to craft a better case for M**A’s approval as a medicine. That will be expensive and time consuming. As FDA’s conclusion reverberates around the world of psychedelics, I will be interested to see how this affects psychedelic operators outside of pathology-focused medical frameworks.”

FDA gives thumbs down to M**A for now, demanding further research The much-anticipated decision has rattled supporters of psychedelic therapies. The drugmaker says it will ask the agency to reconsider.

We’re here to set your business up for success, whether you are a publicly-traded company, closely-held business, or start-up. Our business transactions team is made up of highly experienced transactional attorneys who have worked at AmLaw 100 law firms, big accounting firms, and in-house for public companies and investment banks. Our lawyers have also personally owned and operated start-up companies, so we understand complex legal matters and aim to provide high quality legal services in a cost-effective manner.

Contact Us - Emerge Law Group Call or message us at one of our office locations. Emerge Law Group is conveniently situated to serve your legal needs.

Intellectual property (“IP”) license agreements come in many shapes and flavors. But all IP licenses boil down to one party giving another party permission to use some IP.

IP may include patents, trademarks, copyrights, trade secrets, and rights of publicity. Some license agreements cover one type of IP like a single trademark, or copyrights for a single song, or maybe a single valuable data set. But often a single license agreement covers multiple types of IP.

Check out this two part blog from the Emerge archives, written by shareholder Sean Clancy.

https://emergelawgroup.com/blog/critical-terms-for-intellectual-property-license-agreements-part-1/

https://emergelawgroup.com/blog/critical-terms-for-intellectual-property-license-agreements-part-2/

In this edition of PsychedeLinks:

✨Get Emerge's Hot Take on how Oregon is teaching states how to tax psychedelic mushrooms - with attorney Dave Kopilak.

🍄In-Home Psilocybin Use Should Be Allowed in Oregon for Disabled and Terminally Ill People, Lawsuit Says

🍄New Washington Ballot Measure Would Legalize Psychedelic Plants and Fungi

🍄Health Officials say Mushroom Candies Sold in Oregon Stores Were Poisonous

🍄New Jersey Lawmakers Amend Psilocybin Bill to Focus Only on Therapeutic Use, Removing Broader Legalization Provisions

🍄Psilocybin Therapy, One Year In: Data from One Year of Legal Psilocybin Offers Insights

📺WATCH: Psychedelics Are Now Legal in Australia – With a Catch

emergelawgroup.com

ICYMI: Still have questions about the OLCC CAMP updates and batch tagging? Check out a recent webinar we co-hosted with Kevin Jacoby from Jacoby Law!

OLCC Batch Tagging & CAMP Updates from Jacoby Law and Emerge Law Group Oregon's cannabis industry has already encountered significant regulatory changes in 2024: batch tagging delays and OLCC's new CAMP licensing system. This we...